Stockscreener 앱 받기
43.06
2.89%
-1.28
전일 마감가:
$44.34
열려 있는:
$43.44
하루 거래량:
1.57M
Relative Volume:
1.28
시가총액:
$1.74B
수익:
$147.17M
순이익/손실:
$-408.35M
주가수익비율:
-3.852
EPS:
-11.1787
순현금흐름:
$-299.01M
1주 성능:
-14.27%
1개월 성능:
-55.84%
6개월 성능:
+13.20%
1년 성능:
+59.96%
1일 변동 폭
$41.53
$44.95
1주일 범위
$41.53
$51.15
52주 변동 폭
$20.44
$118.84
Grail Inc Stock (GRAL) Company Profile
명칭
Grail Inc
전화
(833) 694-2553
주소
1525 O'BRIEN DRIVE, MENLO PARK
Compare GRAL vs TMO, DHR, IDXX, A, WAT
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GRAL
Grail Inc
|
43.06 | 1.74B | 147.17M | -408.35M | -299.01M | -11.18 |
|
TMO
Thermo Fisher Scientific Inc
|
464.37 | 172.51B | 44.56B | 6.72B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
187.32 | 132.46B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
573.82 | 45.69B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
111.51 | 31.51B | 7.07B | 1.29B | 993.00M | 4.5355 |
|
WAT
Waters Corp
|
286.57 | 28.11B | 3.17B | 642.63M | 516.49M | 10.77 |
Grail Inc Stock (GRAL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-19 | 개시 | TD Cowen | Hold |
| 2026-02-17 | 개시 | Robert W. Baird | Outperform |
| 2025-12-02 | 재개 | Morgan Stanley | Equal-Weight |
| 2025-11-12 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2025-04-21 | 개시 | Canaccord Genuity | Buy |
| 2024-11-27 | 개시 | Morgan Stanley | Equal-Weight |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-10-17 | 개시 | Guggenheim | Neutral |
모두보기
Grail Inc 주식(GRAL)의 최신 뉴스
Canaccord Genuity Reaffirms Their Buy Rating on GRAIL Inc (GRAL) - The Globe and Mail
GRAIL Inc (GRAL) Shares Down 4.59% on Mar 13 - GuruFocus
Assessing GRAIL (GRAL) Valuation After Recent Share Price Volatility and Narrative Fair Value Gap - simplywall.st
Grail Inc. Announces CEO Transition - Contract Pharma
Grail CEO to retire after failed cancer detection trialSan Francisco Business Times - The Business Journals
GRAIL names Josh Ofman as CEO, Bob Ragusa to retire June 1 - Investing.com Canada
GRAIL, Inc. Hits Day High with 12.18% Surge Amid Market Challenges - Markets Mojo
(GRAL) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Freidin, Grail CFO, sells $154k in GRAL stock - Investing.com Nigeria
Grail CEO Bob Ragusa retiring, Josh Ofman appointed successor - TipRanks
GRAIL, Inc. 2025 Annual Report: Multi-Cancer Early Detection with Galleri, Company Strategy, and Key Business Risks - Minichart
GRAIL, Inc. Announces Chief Executive Officer Changes, Effective June 1, 2026 - marketscreener.com
Cancer detection company GRAIL elevates Josh Ofman to lead multi-cancer efforts - Stock Titan
Levi & Korsinsky, LLP: Grail (GRAL) Guided to 2030 Cash Runway While Key Trial Risk Went Unaddressed - GlobeNewswire
Here's Why Grail Shares Crashed in February and Why it Could Be a Buying Opportunity - AOL.com
Grail Inc’s Earnings Call Balances Momentum and Risk - TipRanks
A Persistent Patient’s Story - RealClearHealth
Aaron Freidin Sells 2,492 Shares of GRAIL (NASDAQ:GRAL) Stock - MarketBeat
Joshua Ofman Sells 2,937 Shares of GRAIL (NASDAQ:GRAL) Stock - MarketBeat
Insider Selling: GRAIL (NASDAQ:GRAL) CEO Sells 7,461 Shares of Stock - MarketBeat
Freidin, Grail CFO, sells $154k in GRAL stock By Investing.com - Investing.com Australia
Ofman Joshua J. (GRAIL) sells $177k in shares - Investing.com South Africa
Grail CEO Ragusa sells $409k in shares - Investing.com India
GRAIL (GRAL) president sells 3,627 shares in automatic tax sell-to-cover - Stock Titan
GRAL Stock Price, Quote & Chart | GRAIL INC (NASDAQ:GRAL) - ChartMill
Samsung and GRAIL Announce Strategic Collaboration To Bring GRAIL’s Galleri® Multi-Cancer Early Detection Test to Asia - samsung.com
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - The Cancer Letter
GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.” Mainstream epidemiologists beg to differ - The Cancer Letter
GRAIL, Inc. $GRAL Shares Purchased by JPMorgan Chase & Co. - MarketBeat
How Investors Are Reacting To GRAIL (GRAL) Mixed NHS-Galleri Trial Results And Ongoing Net Losses - Sahm
POM Health Announces Agreement with GRAIL to Offer Its Galleri® MCED Test - PR.com
Here's Why Grail Stock Bounced Back 16% Today - AOL.com
Levi & Korskinsky, LLP: Grail (GRAL) Guided to 2030 Cash Runway While Key Trial Risk Went Unaddressed - GlobeNewswire
Vanguard Group Inc. Trims Stock Position in GRAIL, Inc. $GRAL - MarketBeat
Crcm LP Has $108.96 Million Holdings in GRAIL, Inc. $GRAL - MarketBeat
GRAIL, Inc. Hits Day Low of $41.50 Amid Price Pressure - Markets Mojo
GRAL DROPS ~50% -- REPORTED NUMBERS VS. ACTUAL RESULTS; LEVI & KORSINSKY, LLP INVESTIGATES - Seeking Alpha
Grail Insider Sold Shares Worth $1,881,417, According to a Recent SEC Filing - marketscreener.com
GRAIL (NASDAQ:GRAL) CFO Aaron Freidin Sells 9,573 Shares - MarketBeat
Insider Selling: GRAIL (NASDAQ:GRAL) CEO Sells 37,504 Shares of Stock - MarketBeat
GRAL | GRAIL, Inc. Common Stock FinancialsIncome Statement - Quiver Quantitative
GRAIL (GRAL) president gets RSU grant, sells shares for taxes - Stock Titan
GRAIL (GRAL) CFO awarded 60,118 RSUs, sells shares to cover taxes - Stock Titan
GRAIL (GRAL) CEO sells 37,504 shares in automatic tax sell-to-cover - Stock Titan
GRAIL, Inc. (GRAL) Stock Analysis: Investor Outlook On A 67.21% Potential Upside - DirectorsTalk Interviews
GRAL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
GRAIL, Inc. Hits Day Low of $52.56 Amid Price Pressure - Markets Mojo
GRAL: NHS-Galleri trial showed strong stage 4 cancer reduction and broad commercial momentum - TradingView
GRAIL (GRAL) Valuation Check As NHS Galleri Trial Data And Earnings Reset Growth Expectations - simplywall.st
GRAL: Affiliate to sell 36,923 vested RSU shares (Form 144) - Stock Titan
GRAL (NASDAQ) insider sale: Robert Ragusa sells 40,000 shares; 74,873 RSUs vested - Stock Titan
Grail Inc (GRAL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.34%
0.59%
자본화:
|
볼륨(24시간):